Latest News and Press Releases

Pooled analyses of the Phase 3 CAMP studies in molluscum contagiosum showed VP-102 achieved statistically significantly higher rate of complete lesion clearance and percentage of subjects with >...

WEST CHESTER, Pa., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of...

WEST CHESTER, Pa., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of...

WEST CHESTER, Pa., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of...

WEST CHESTER, Pa., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of...

-Achieved positive topline results from Phase 2 clinical trial of VP-102 in patients with common warts -Enrolled first patient in a Phase 2 trial of VP-102 for the treatment of external genital warts...

WEST CHESTER, Pa., June 27, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel...

51% of subjects in Cohort 2 achieved complete clearance of all treatable warts VP-102 was well-tolerated with no serious adverse events reported Common warts affect approximately 22 million people...

WEST CHESTER, Pa., May 21, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel...

-Reported positive topline data from pivotal Phase 3 clinical trials of VP-102 for the treatment of molluscum contagiosum -Preparing to submit NDA in second half of 2019 WEST CHESTER, Pa., May 07,...